首页 正文

Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort

{{output}}
Background: FOLFIRINOX is a standard first-line therapy for metastatic pancreatic ductal adenocarcinoma (PDAC), but its toxicity often necessitates dose adjustments. This study evaluated the impact of first relative dose intensit... ...